Pulmonary hypertension (PH) is a life-threatening complication of several, different connective tissue diseases, including systemic lupus erythematous (SLE), systemic sclerosis, and rheumatoid arthritis. PH can present early in SLE. The severity does not correlate with other organ disease activity or with disease duration. It is still debatable whether immunosuppressive therapy is useful for PH related to SLE or autoimmune connective tissue disease, as there are no large clinical trials. However, several case reports have shown improvement with cyclophosphamide and prednisone with or without vasodilator therapy. We present a case of SLE-related PH in which a dramatic improvement in mean pulmonary artery pressure and exercise capacity was noted after the institution of treatment with mycophenolate mofetil, resulting in a decrease in corticosteroid dose. Our observations support the potential value of mycophenolate mofetil therapy for PH in SLE.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5875974 | PMC |
| http://dx.doi.org/10.7759/cureus.2121 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Although granulomatous interstitial nephritis (GIN) is a rare histological finding in kidney transplants, the joint occurrence of GIN and focal segmental glomerulosclerosis (FSGS) has not, to our knowledge, been reported in the literature. We report a case of GIN and de novo FSGS in kidney transplant recipients leading to allograft failure. A 69-year-old male with a history of end-stage renal disease (ESRD) of unknown etiology, as well as liver failure from hepatitis B and C co-infection, initially had a living unrelated kidney transplant (LURT) in 2007 and subsequently received both liver and kidney transplants (SLKTs) in 2017.
View Article and Find Full Text PDFA case of relapsed gAChR-positive autoimmune autonomic ganglionopathy treated by plasma exchange and mycophenolate mofetil.
Front Neurol
January 2025
Department of Neurology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
Autoimmune autonomic ganglionopathy (AAG) is a rare and acquired immune-mediated disease that leads to wide autonomic failure, mainly characterized by orthostatic hypotension, gastrointestinal dysfunction, anhidrosis and poorly reactive pupils. This disorder is usually associated with autoantibodies to the ganglionic nicotinic acetylcholine receptor (gAChR-Ab). In this study, we describe a case of a gAChR-Ab-positive AAG patient with two therapeutic stages.
View Article and Find Full Text PDFInfection risk of rituximab monotherapy versus combination therapy with rituximab and mycophenolic acid in systemic sclerosis: A retrospective cohort study.
J Am Acad Dermatol
January 2025
Department of Dermatology, Brigham and Women's Hospital, Boston, MA; Harvard Medical School, Boston, MA. Electronic address:
Update in Clinical Science: Autoimmune Hepatitis.
J Hepatol
January 2025
I. Department of Medicine, University Medical Centre Hamburg-Eppendorf, Hamburg, Germany; European Reference Network on Hepatological Diseases (ERN RARE-LIVER). Electronic address:
Autoimmune hepatitis (AIH) is an enigmatic, relatively rare disease with a variable spectrum of presentation whose pathogenesis, diagnosis and management remain a major challenge. Methods. We have performed a review incorporating recent developments in basic science, epidemiology, clinical science, therapeutics, regulatory science and evaluated the challenges associated with the application of translational research and clinical trial design to a condition that is a chameleon in nature, where outcomes range from relatively benign disease through cirrhosis and acute liver failure.
View Article and Find Full Text PDFPotential therapeutics and vaccines: Current progress and challenges in developing antiviral treatments or vaccines for Oropouche virus.
Diagn Microbiol Infect Dis
January 2025
Department of Pharmacy Practice, ISF College of Pharmacy, Moga, Punjab, 142001 India. Electronic address:
Oropouche virus (OROV), an emerging arbovirus, poses a significant public health challenge in tropical and subtropical regions, with no licensed vaccines or antiviral therapies currently available. This review explores recent advancements in therapeutic strategies and vaccine development for OROV, focusing on molecular mechanisms of viral replication, identification of potential antiviral targets, and the role of immunotherapy in managing infections. Promising antiviral candidates, including ribavirin, mycophenolic acid, and interferon, have demonstrated efficacy in in vitro studies, offering a foundation for further investigation.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!